UK govt sets sights on being AI drug discovery ‘world leader’

Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

As AI shakes up pharma and biotech, can patent law keep up?

22 May 2025 Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.

Americas

ADCs, TCR, and multimodal AI: Transformative trends in 2025

23 January 2025 Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.

Americas

Big Pharma counsel embrace AI but data and legal risks loom

24 October 2024 Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.

More features

Why AI is changing the patent rules faster than anyone can keep up

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Data and delivery: Inside AI's inventorship dilemma

UK govt sets sights on being AI drug discovery ‘world leader’

More on this story

Editor's picks

Editor's picks

More features